AI-based cardiac monitoring startup Huinno announced on Monday a strategic partnership with Yuhan USA Corporation to expand its reach into the US digital healthcare market.
The agreement will see the two companies collaborating on sales channel development, localized marketing, support for regulatory approval, logistics, and operations, with the goal of accelerating Huinno’s entry into the US market.
The partnership focuses on the rollout of Huinno’s artificial intelligence-powered electrocardiogram (ECG) monitoring solutions, including MEMO Patch M, MEMO Cue, and MEMO Care, alongside its clinical prediction platform, Vital-PICASO.
MEMO Patch M is a lightweight, wearable ECG device designed for continuous monitoring for up to eight days, ensuring stable measurements even in high-risk clinical environments. MEMO Cue builds on this by analyzing inpatient ECG data in real-time, facilitating early detection of abnormalities and faster clinical decision-making. The system can be implemented using existing hospital infrastructure, requiring no additional network investment.
MEMO Care extends monitoring beyond hospital settings, leveraging AI to analyze up to 14 days of ECG data in home and outpatient environments.
Vital-PICASO, developed by Huinno’s subsidiary Huinno AIM, analyzes patient vital signs to predict clinical deterioration, including hypotension, hypoxia, and cardiac arrest.
The company stated that this partnership combines its innovative AI-driven monitoring technologies with Yuhan USA’s established local commercialization capabilities, aiming to accelerate adoption within the US healthcare system.
“Our goal is to improve patient safety and medical efficiency by providing solutions tailored to the US market, while simultaneously strengthening our presence in the global digital healthcare sector,” said Huinno CEO Gil Yeong-joon.
jwjeon7625
